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SPONASTRIME dysplasia is an autosomal recessive spondyloepimetaphyseal 
dysplasia characterized by spine abnormalities (spondylar), midface hypoplasia with a 
depressed nasal bridge, metaphyseal striations, and disproportionate short stature.  
Scoliosis, coxa vara, childhood cataracts, short dental roots, and 
hypogammaglobulinemia have also been reported in this disorder. Although an 
autosomal recessive inheritance pattern has been hypothesized, pathogenic variants in 
a specific gene have not been discovered in individuals with SPONASTRIME dysplasia. 
Here, we identified biallelic variants in TONSL, which encodes the Tonsoku-like DNA 
repair protein, in nine individuals from eight families with SPONASTRIME dysplasia, 
and four subjects from three families with short stature of varied severity and 
spondylometaphyseal dysplasia with or without immunologic and hematologic 
abnormalities but no definitive metaphyseal striations at diagnosis. The finding of early 
embryonic lethality in a Tonsl-/- murine model, and the discovery of reduced length, 
spinal abnormalities, reduced numbers of neutrophils and early lethality in a tonsl-/- 
zebrafish model, support the hypomorphic nature of the identified TONSL variants. 
Moreover, functional studies revealed increased levels of spontaneous replication fork 
stalling and chromosomal aberrations and fewer camptothecin (CPT)-induced RAD51 
foci in subject-derived cell lines. Importantly, these cellular defects were rescued upon 
re-expression of wild type TONSL, consistent with the hypomorphic TONSL variants 
being pathogenic.  Overall, our studies in humans, mouse, zebrafish, and subject-
derived cell lines confirm that pathogenic variants in TONSL impair DNA replication and 
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homologous recombination-dependent repair processes and lead to a spectrum of 

























SPONASTRIME dysplasia (MIM: 271510) is an autosomal recessive 
spondyloepimetaphyseal dysplasia named for characteristic clinical and radiographic 
findings including spine abnormalities (spondylar), midface hypoplasia with a depressed 
nasal bridge, and striation of the metaphyses 1. Additional features include 
disproportionate short stature with exaggerated lumbar lordosis, scoliosis, coxa vara, 
limited elbow extension, childhood cataracts, short dental roots, and 
hypogammaglobulinemia 2-9. Radiographically, the abnormalities of the lumbar vertebral 
bodies are suggested to be the most specific finding because the characteristic 
metaphyseal striations may not be apparent at young ages 10. Multiple affected siblings 
have been reported with SPONASTRIME dysplasia 1; 2; 6, and thus, an autosomal 
recessive inheritance pattern has been suspected. However, no gene has been 
associated with this disorder. 
To identify a genetic basis for SPONASTRIME dysplasia, we performed whole 
exome sequencing and identified variants in TONSL (MIM: 604546) in individuals with 
this diagnosis and in individuals with other skeletal dysplasia phenotypes. We used 
studies in knockout mouse and zebrafish models and functional studies in subject-derived 
fibroblasts to demonstrate the essential nature of TONSL and show that reduced TONSL 
function is associated with replication fork and chromosomal instability, which likely 
contributes to the phenotypes observed in individuals with biallelic TONSL variants. 
 
Materials and Methods 
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Human subjects and sequencing studies. Informed consent for all subjects (except 
subject 11) was obtained in accordance with research protocols that were approved by 
the Institutional Review Board at Baylor College of Medicine (BCM), the National 
Institutes of Health, or at local institutions prior to testing. Sample for subject 11 was 
obtained from the Biobank, and consent was obtained as per the protocol for Biobank 
submission 11.  For subjects 2, 3-1, 4, 7-1, and 7-2, informed consent for publication of 
photographs was obtained.  
DNA was extracted from peripheral blood mononuclear cells for exome 
sequencing. For families 1, 2, 9 and 11, exome sequencing was performed at the Human 
Genome Sequencing Center (HGSC) at Baylor College of Medicine. Using 1 ug of DNA 
an Illumina paired-end pre-capture library was constructed according to the 
manufacturer’s protocol (Illumina Multiplexing_SamplePrep_Guide_1005361_D) with 
modifications as described in the BCM-HGSC Illumina Barcoded Paired-End Capture 
Library Preparation protocol.  Pre-capture libraries were pooled into 4-plex library pools 
and then hybridized in solution to the HGSC-designed Core capture reagent 12 (52Mb, 
NimbleGen) or 6-plex library pools used the custom VCRome 2.1 capture reagent1 
(42Mb, NimbleGen) according to the manufacturer’s protocol (NimbleGen SeqCap EZ 
Exome Library SR User’s Guide) with minor revisions. The sequencing run was 
performed in paired-end mode using the Illumina HiSeq 2000 platform, with sequencing-
by-synthesis reactions extended for 101 cycles from each end and an additional 7 cycles 
for the index read. With a sequencing yield of 10.6 Gb, the sample achieved 91% of the 
targeted exome bases covered to a depth of 20X or greater. Illumina sequence analysis 
was performed using the HGSC Mercury analysis pipeline 13; 14 which moves data through 
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various analysis tools from the initial sequence generation on the instrument to annotated 
variant calls (SNPs and intra-read in/dels). For subject 3-1, trio exome sequencing was 
performed at ARUP Laboratories using Illumina SureSelect XT kit reagents and a 
HiSeq2500 platform (Illumina, San Diego, CA), and the identified variants in TONSL were 
confirmed in subject 3-2 using Sanger sequencing. For family 5, exome capture was 
performed at the genomic platform of the IMAGINE Institute (Paris, France) with the 
SureSelect Human All Exon kit (Agilent Technologies). Agilent SureSelect Human All 
Exon (V4) libraries were prepared from 3 μg of genomic DNA sheared with Ultrasonicator 
(Covaris) as recommended by the manufacturer. Barcoded exome libraries were pooled 
and sequenced using HiSep2500 (Illumina) generating paired-end reads. After 
demultiplexing, sequences were mapped on the human genome reference (NCBI 
build37/hg 19 version) with BWA 15. The mean depth of coverage obtained for each 
sample was ≥ x80 with 95% of the exome covered at least x15. Variant calling was carried 
out with the Genome Analysis Toolkit (GATK) 16, SAMtools 17 and Picard Tools. Single 
nucleotide variants were called with GATK Unified Genotyper, whereas indel calls were 
made with the GATK IndelGenotyper_v2. All variants with a read coverage ≤x2 and a 
Phred-scaled quality of ≤20 were filtered out. All the variants were annotated and filtered 
using an in-house developed annotation software system (Polyweb, unpublished). We 
first focused our analyses on non-synonymous variants, splice variants, and coding 
indels. The potential pathogenicity of variants was evaluated using SIFT 18 (cutoff ≤0.05), 
PolyPhen2 19 (HumVar scores, cutoff ≥0.447) and Mutation Taster 20 (cutoff: qualitative 
prediction as pathogenic) prediction algorithms. We also assessed frequency in control 
populations and datasets including the ExAC database, dbSNP129, the 1000 Genomes 
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project, ClinVar, HGMD and in-house exome data. All variants (except the variants in 
subject 14) were confirmed by Sanger sequencing and correct family segregation was 
verified. For family 6, exome sequencing was performed as described previously 21. 
Family 7, which was enrolled in the Undiagnosed Diseases Network, and family 8 had 
exome sequencing at Baylor Genetics Laboratories, as described elsewhere22. Codified 
genomics variation interpretation software was used for variant review in families 7 and 
8. Exome sequencing and analysis was performed as described previously for subject 
1023, subject 1224, and subject 1324. For subject 14, exome was sequenced at CEGH-
CEL-Universidade de São Paulo, the capture library was an Illumina TrueSeq kit, 
sequencing was done an on Illumina HiSeq, alignment with the Burrows-Wheeler Aligner 
(BWA), and annotation with GATK/ ANNOVAR. Sanger sequencing of the TONSL exons 
was performed in DNA from subject 4 and 15 using primers in Table S1. Sanger 
confirmations were performed using Big Dye® Terminator v3.1 and an ABI 3730 DNA 
Analyzer (Life Technologies, Carlsbad, CA). Sanger confirmation for subject 2 was 
performed by submission of PCR products to Genewiz (La Jolla, CA). All variants are 
provided using hg19, NM_013432.4. 
 
Tonsl-/- mouse generation and analysis. Single guide RNA (sgRNA) sequences were 
selected to target intronic sequences flanking exons 12-18 of Tonsl (chr15:76,635,006-
76,635,028 and chr15:76,632,468-76,632,490; GRCm38/mm10) using the Wellcome 
Trust Sanger Institute (WTSI) Genome Editing website 25. DNA templates for in vitro 
transcription of sgRNAs were produced using overlapping oligonucleotides in a high-
fidelity PCR reaction 26 and sgRNA was transcribed using the MEGA shortscript T7 kit 
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(ThermoFisher, Waltham, MA). Cas9 mRNA was purchased from ThermoFisher.  Cas9 
mRNA (100 ng/µl) and sgRNA (10 ng/µl) in RNase-free 1xPBS were injected into the 
cytoplasm of 100 pronuclear stage C57Bl/6NJ embryos. Primers P1 (5’ 
CTTCAGCTGGTGGCCACAT), P2 (5’ TCTCCCATGTCATTGCGCC), P3 (5’ 
GCCCTCTCTAAGGCCCATAG) were used for genotyping and sequencing founder 
animals and subsequent generations (P1 and P2 amplify the wild-type allele; P1 and P3 
amplify the null allele). All mouse studies were approved by the BCM Institutional Animal 
Care and Use Committee (IACUC).   
 
tonsl-/- zebrafish generation and analysis. Zebrafish were raised according to standard 
protocols 27 and in accordance with University of Oregon IACUC protocols. Oregon AB* 
and Tg(mpx:GFP)i114 lines were used 28 . The zebrafish-Codon-Optimized Cas9 plasmid 
29 that was digested with XbaI, purified and transcribed using T3 message machine kit 
(Ambion, Austin, USA). gRNA was designed (using the ZiFiT Targeter software) to the 
CRISPR target sequence GGAGAGTGCTATGCAGAGCT at the 3’ end of tonsl exon 3. 
Templates for gRNA synthesis were prepared by PCR using the gene-specific primer: 5`- 
AATTAATACGACTCACTATA-[20 bp Target Sequence]-GTTTTAGAGCTAGAAATAGC-
3` and the gRNA scaffold primer: 5`-
GATCCGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTT
AACTTGCTATTTCTAGCTCTAAAAC-3` using an annealing temperature of 60°C. 
sgRNA was synthesized using T7 Megascript kit, (Ambion, Austin, USA). Cas9 mRNA 
(300 ng/µl) and sgRNA (150 ng/µl) were mixed and injected into Oregon AB* wild-type 
zebrafish embryos at the one cell stage using an MPPI-2 Pressure Injector with a BP-15 
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Back Pressure Unit (Applied Scientific Instrumentation, Oregon USA). Sequence analysis 
of pools of injected embryos at 24 hours post fertilization (hpf) using primers Tonsl e3-
6F:CCCTAGGTGACTATCAAGCTGC and Tonsl e3+129R 
ACATGCATGCGTTTACTGTAGC to amplify the region containing the target sequence 
confirmed CRISPR activity at the target site, and analysis of individual F1 embryos at 24 
hpf identified clutches carrying frameshift mutations, which were then propagated and 
crossed to examine the recessive phenotype. Two frameshift deletions of 5 and 13 bp, 
respectively, affecting both alternate 5’ – 3’ reading frames in exon 3, were recovered in 
F1 progeny of injected founders. Skeletal elements were stained with Alcian Blue and 
Alizarin Red as previously described 30 .  Images were    captured using a Leica S8APO 
dissecting microscope fitted with a Leica EC3 camera and LAZ EZ imaging software. 
Statistical analyses were performed using GraphPad software.  
 
Cell culture and generation of cell lines. Dermal primary fibroblasts were grown from skin-
punch biopsies and maintained in Dulbecco's modified Eagle's medium (DMEM; Life 
Technologies) supplemented with 20% FCS, 5% L-glutamine and 5% penicillin-
streptomycin (Invitrogen) antibiotics. Subject-derived cell lines were validated using 
Sanger sequencing and immunoblotting. Primary fibroblasts were immortalized with 
293FT-derived supernatant containing a human telomerase reverse transcriptase (TERT) 
lentivirus that was generated using the plasmids: pLV-hTERT-IRES-hygro (gift from 
Tobias Meyer; Addgene #85140), psPax2 (gift from Didier Trono; Addgene #12260) and 
pMD2.G (gift from Didier Trono; Addgene #12259). Selection was performed using 
hygromycin (Invitrogen) at 70 μg/ml. Fibroblast complementation was carried out using a 
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lentiviral vector encoding Flag-tagged TONSL (gift from Dr. Yonghwan Kim). All cell lines 
were routinely tested for mycoplasma. ATLD2 is a fibroblast cell line derived from an 
individual with ataxia-telangiectasia-like disorder (ATLD, MIM:604391) who has biallelic 
pathogenic variants in MRE11 (MIM:600814) 31. 
 
Immunoblot analysis and antibodies. Whole-cell extracts were prepared from harvested 
subject-derived fibroblasts by sonication in UTB buffer (8 M urea, 50 mM Tris, 150 mM β-
mercaptoethanol). Whole-cell extracts were then analyzed by SDS–PAGE on 6% 
acrylamide gels following standard procedures. Protein samples were transferred onto a 
nitrocellulose membrane, and immunoblotting was performed using antibodies to TONSL 
(1:200; the kind gift of D. Durocher, Toronto, Canada) 32 and DNA-PKCS (Santa Cruz 
Biotechnology, [G-4] sc-5282; 1:2000).   
 
Immunofluorescence and fluorescence microscopy. Subject-derived fibroblasts were 
seeded onto coverslips at least 48 h before extraction and fixation. Cells were pre-
extracted for 5 min on ice with ice-cold buffer (25 mM HEPES, pH 7.4, 50 mM NaCl, 1 
mM EDTA, 3 mM MgCl2, 300 mM sucrose and 0.5% Triton X-100) and then fixed with 
4% paraformaldehyde for 10 min. Fixed cells were stained with primary antibodies 
specific to γH2AX (Millipore, 05-636; 1:1,000) and RAD51 (Merck, PC130; 1:500), with 
secondary antibodies conjugated to Alexa Fluor 488 and Alexa Fluor 594 (Life 
Technologies), and then with DAPI. Images were visualized using a Nikon Eclipse Ni 





DNA-fiber-spreading assay. Subject-derived fibroblasts were seeded for at least 48 h 
prior to harvesting. Cells were pulse-labelled with 25 µM CldU for 30 min, washed with 
PBS, pulse-labelled with 250 µM IdU with or without 50 nM CPT, and harvested by 
trypsinization. The cells were washed with PBS and resuspended to a concentration of 5 
× 105/ml in PBS. The cells were then lysed in spreading buffer (200 mM Tris-HCl, pH 7.5, 
50 mM EDTA, 0.5% SDS) directly on glass microscope slides, and DNA fibers were 
allowed to spread down the slide by gravity. The slides were then fixed in methanol:acetic 
acid (3:1 ratio), denatured with 2.5 M HCl, and CldU and IdU was detected using rat anti-
BrdU antibody (clone BU1/75, ICR1; Abcam, ab6326; 1:750) and mouse anti-BrdU 
antibody (clone B44; BD Biosciences, 347583; 1:750). Slides were fixed in 4% 
paraformaldehyde before immunostaining with secondary antibodies conjugated to Alexa 
Fluor 594 or Alexa Fluor 488 (Life Technologies). Labelled DNA fibers were visualized 
using a Nikon Eclipse Ni microscope with 60× oil-immersion objectives and images were 
acquired using NIS-Elements software (Nikon Instruments). Replication fork structures 
(>1000 fork structures) and CldU/IdU track lengths (>300 ongoing forks) were then 
quantified using ImageJ software (US National Institutes of Health; NIH). 
 
Metaphase spreads. Giemsa-stained metaphase spreads were prepared as previously 
described21. Briefly, Colcemid (KaryoMAX™, Life Technologies) was added at a final 
concentration of 0.2 μg/ml for 4 hours. Cells were then harvested by trypsinization, 
subjected to hypotonic shock for 30 min at 37 °C in hypotonic buffer (10mM KCl, 15% 
FCS) and fixed in 3:1 ethanol:acetic acid solution. Cells were dropped onto acetic-acid-
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humidified slides, stained for 15 min in Giemsa-modified solution (Sigma; 5% vol/vol in 
water) and washed in water for 5 min. 
 
Statistics 
Statistical analysis was performed as indicated in tables and in figure legends. 
Significance is indicated by a p value of less than 0.05. 
 
Results 
Biallelic variants in TONSL cause a spectrum of skeletal dysplasia phenotypes 
We performed exome sequencing in 10 probands with a clinical diagnosis of 
SPONASTRIME dysplasia who were identified by the Baylor-Texas Children’s Hospital 
Skeletal Dysplasia Program, the International Skeletal Dysplasia Registry, GeneMatcher 
33 and various collaborators who are experts in skeletal dysplasias (Table 1, Table S2 
and S3). Biallelic variants in TONSL, which encodes the Tonsoku-like DNA repair protein, 
were identified in six of the ten subjects with SPONASTRIME dysplasia (Table 2). Two 
additional subjects (subjects 4 and 15) with SPONASTRIME dysplasia and biallelic 
variants in TONSL were identified by Sanger sequencing of the coding region of the gene 
(Table 1, 2, S2). In addition, subject 3-2 was confirmed to have the same variants in 
TONSL as his sibling (3-1) using Sanger sequencing. These nine subjects had significant 
disproportionate short stature, spine abnormalities, and characteristic facial features 
including midface hypoplasia with a depressed nasal bridge (Figure 1A, Figures S1, Table 
S2). All but the youngest subject (3-2) also had metaphyseal striations. Other features 
included bilateral cataracts in three subjects, subglottic stenosis in three subjects, shallow 
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dental roots in four subjects, and a history of hypogammaglobinemia in two subjects. 
Clinical information about subject 4 and 15 has been published previously 4; 7; 8. Biallelic 
variants in TONSL or in MMS22L (MIM: 615614), the gene encoding the binding partner 
for TONSL, were not detected in the other four subjects (subjects 9 – 12) with a clinical 
diagnosis of SPONASTRIME dysplasia suggesting that this phenotype is genetically 
heterogeneous (Table S3). However, single heterozygous variants in TONSL were 
identified in subjects 9 and 10 (the p.Arg934Trp variant, which was also identified in 
individuals 1, 3, 14 and 15, and a splice site variant, respectively). Thus, we cannot rule 
out the possibility that deep intronic variants, promoter variants or large intragenic 
rearrangements/deletions in TONSL could be present in subjects 9 - 12. In the two 
subjects without any TONSL rare variants (subjects 11 and 12), exome analysis did not 
identify any sharing of genes with rare variants, nor did the analysis reveal any variants 
in genes encoding for TONSL interactors or related proteins.   
Simultaneously, exome sequencing independently revealed biallelic variants in 
TONSL in three subjects (7-1, 7-2, and 8) from two families with spondylometaphyseal 
dysplasia and immunologic and hematologic abnormalities (hypogammaglobulinemia 
and neutropenia, respectively) and in subject 6 who had spondylometaphyseal dysplasia 
with severe short stature, primary aphakia, and absent pupils. Detailed clinical information 
is provided in Table 1, 3, S2, S3, S4 and Figure 1A, S1. All individuals except two 
(subjects 3-1 and 3-2) had a frameshift, nonsense or splice variant in combination with a 
missense variant in TONSL. All missense variants had CADD scores greater than 15 34, 
and all but one of the missense variants were predicted to be damaging or probably 
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damaging by both SIFT and Polyphen-2 18; 19 . The variants are provided in Table 2 and 
4 and in Figure 1B.  Details regarding the exome analysis are provided in Table S5. 
Since all subjects except the siblings from family 3 had one frameshift, nonsense, 
or splice variant associated with an amino acid substitution, we hypothesized that biallelic 
partial loss of TONSL function may explain the phenotype in our subjects. To investigate 
the impact of variants identified in our subjects on TONSL protein stability, we performed 
immunoblot analyses on three subject-derived fibroblast cell lines that had a range of 
TONSL variants. This analysis revealed the cell line from subject P6 
(p.Gln713*;p.Thr653Met) produced little to undetectable levels of full length TONSL 
protein (Figure 1C), perhaps reflecting the deleterious impact of the two variants on 
TONSL protein stability. However, since the antibody used was raised against a fragment 
of recombinant TONSL comprising residues 559-809, a region encompassing both 
mutations in P6, it cannot be ruled out that the absence of a signal may result from the 
loss of the epitope recognition. Interestingly, in contrast, near normal levels of TONSL 
protein were detected in cell lines derived from subjects P3-1 
(p.Arg934Trp;p.Ser1197Pro) and P7-1 (p.Glu199Lys;c.866-1G>C) (Figure 1C), indicating 
that individual TONSL variants have a differential effect on protein stability. Of note, the 
anti-TONSL antibody used for Western blotting detected two major bands. While the 
origin of these is unclear, we hypothesize that they represent either different isoforms or 
that this is caused by post-translational modification of the protein. 
 
Early lethality in mouse and zebrafish models of TONSL deficiency 
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To investigate the impact of TONSL deficiency on development with in vivo 
models, we identified a Tonsl knockout mouse that was generated by the BCM Knockout 
Mouse Phenotyping Program (KOMP2). Exons 12 to 18 of Tonsl were deleted in a 
knockout mouse (Tonslem1(IMPC)Bay, Tonsl-/-) which was generated using CRISPR-Cas9 
technology as described previously 35; 36 (Figure S3). Deletion of these exons is predicted 
to result in a frameshift and premature stop codon leading to nonsense mediated decay. 
In collaboration with KOMP2, we detected no homozygous Tonsl-/- mice at weaning 
(Table 5). Moreover, embryonic genotyping was performed, and no homozygous mice 
were detected as early as E9.5, suggesting that murine Tonsl deficiency causes lethality 
early in embryogenesis (Table 5).  
To investigate the impact of TONSL deficiency on embryonic development further, 
we used CRISPR/Cas9 to generate early frameshift mutations in the zebrafish tonsl gene 
(Figure S4). Zebrafish tonsl-/- mutants undergo normal embryonic development and are 
indistinguishable from wild-type siblings up to 6 days post fertilization (dpf), but begin to 
show reduced fitness and delayed growth thereafter (Figure 2A-B), with 100% mortality 
observed before 20 dpf. Using cartilage and bone staining to examine skeletal 
development, we observed that ossification of vertebral bodies around the notochord was 
significantly accelerated in tonsl-/- larvae at 7 dpf compared to wild-type siblings (Figure 
2C). Because of the clinical findings of neutropenia in a subset of individuals in this study, 
we crossed carriers of the truncating tonsl alleles into a transgenic zebrafish line in which 
neutrophils fluoresce from day 2 onward. We observed normal neutrophil development in 
Tg(mpo:gfp;tonsl-/-) mutants through 6 dpf, followed by diminishing neutrophil numbers 
correlated with the progressive decline in fitness characteristic of these mutants (Figure 
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2D-E). Although analysis is somewhat limited by early lethality, the larval phenotypes are 
reminiscent of the short stature and immunologic and spinal abnormalities exhibited by 
individuals with pathogenic variants in TONSL, which progressively gets worse with age 
and development (Table 1, 3, S2, S4). Together, these in vivo models of TONSL 
deficiency demonstrate the essential function of the protein. 
 
Defective formation of RAD51-induced foci in fibroblast cell lines derived from individuals 
with TONSL variants 
TONSL is homologous to the plant DNA repair protein, Tonsuku/Brushy1/Mgoun3 
and is necessary for the repair of replication-associated DNA damage in conjunction with 
its obligate binding partner, MMS22L 32; 37-39. Although the TONSL-MMS22L complex is 
reported to bind to all replication forks, increased binding has been noted at stalled forks 
and sites of DNA damage 32; 37-40, where the complex promotes efficient homologous 
recombination (HR)-dependent repair and the restart of stalled replication forks by 
stimulating RAD51-ssDNA nucleofilament formation 38; 40. As a consequence, loss of 
TONSL leads to increased levels of S-phase associated DNA damage, defective HR and 
renders cells hypersensitive to DNA damage inducing agents, such as the topoisomerase 
1 inhibitor camptothecin (CPT) 32; 37-40. 
Given the lethality of TONSL deficiency in murine and zebrafish models, we 
investigated the functional effects of TONSL variants using subject-derived cell lines. 
Fibroblast cell lines were successfully generated from three subjects and attempted in 
two additional subjects, but the cell lines from these two subjects failed repeatedly due to 
poor growth, a finding which was not unexpected given the function of TONSL during 
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DNA replication. Consistent with the role of TONSL in promoting RAD51 nucleofilament 
formation, all three subject-derived cell lines exhibited defective formation of CPT-induced 
RAD51 foci as measured by immunofluorescence (Figure 3A-B).  
Following this, we used the DNA fiber technique to assess the impact of the 
TONSL variants on replication fork dynamics 41; 42. This analysis revealed that all three 
subject-derived cell lines exhibited a significant increase in levels of spontaneously stalled 
replication forks, with a concurrent decrease in ongoing forks, demonstrating that defects 
in TONSL give rise to replication fork instability (Figure 4A and 4B). We next investigated 
the ability of subject-derived cell lines to replicate in the presence of CPT. To this end, we 
performed DNA fiber analysis with low dose CPT (50nM) co-incubated with the second 
label (IdU) (Figure 4A). We then measured IdU tract length (normalized to CldU tract 
length), as a readout of the rate of replication fork progression in the presence of CPT. 
Strikingly, two of the three subject-derived cell lines (P6 and P7-1) exhibited significantly 
reduced rates of replication fork progression in the presence of CPT (expressed as a ratio 
of IdU / CldU tract length) (Figure 4C), consistent with the role for TONSL in promoting 
DNA replication in the presence of DNA damage 37. The P3-1 cell line did not exhibit a 
detectable reduction in replication fork progression upon CPT exposure. This raises the 
possibility that either not all of the TONSL variants have the same level of impact on 
TONSL function or that the DNA fibre assay used is not sensitive enough to detect mild 
defects in replication fork progression. However, these findings could, in part, explain the 
variation in clinical phenotypes exhibited by the individuals with TONSL variants. 
To confirm that this observed cellular defects were due to variants in TONSL, we 
complemented two subject-derived fibroblast cell lines (P3-1 and P6) with either an empty 
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vector or a vector expressing Flag-tagged wild type TONSL using a lentiviral expression 
system (Figure 5A). Importantly, re-expression of wild type TONSL rescued CPT-induced 
RAD51 foci formation and reduced the spontaneous replication fork instability observed 
in both P3-1 and P6 fibroblast cells lines (Figure 5B-D). Furthermore, the reduced rates 
of replication fork progression in the presence of CPT exhibited by P6 was also corrected 
(Figure 5E). 
Lastly, to ascertain the pathogenic impact that the increased replication fork 
stalling may have on genome stability, we assessed metaphase spreads from the 
complemented subject-derived fibroblast cell lines for increased spontaneous 
chromosome breakage. In keeping with the observed replication abnormalities, both 
subject-derived fibroblast cell lines complemented with the empty vector exhibited 
increased levels of spontaneous chromosomal aberrations, which was rescued upon re-
expression of wild type TONSL. This demonstrates that the replication defects observed 
in subject-derived cell lines gives rise to increased genome instability (Figure 6A-B). 
Taken together, these data confirm at the cellular level the pathogenicity of the TONSL 




 In this study, we demonstrate that biallelic variants in TONSL are associated with 
a spectrum of skeletal dysplasia phenotypes ranging from clinical SPONASTRIME 
dysplasia with marked disproportionate short stature to mild short stature with 
immunologic and hematologic abnormalities in 13 subjects from 11 families. We also 
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show that several clinical features of these subjects are recapitulated by the zebrafish 
tonsl knockout model. Importantly, TONSL is the first gene associated with the 
SPONASTRIME dysplasia phenotype. In contrast, we were unable to identify variants in 
TONSL or MMS22L in four subjects with a clinical diagnosis of SPONASTRIME dysplasia 
using exome sequencing. This result suggests that SPONASTRIME dysplasia is 
genetically heterogeneous. An alternative hypothesis is that non-coding variants in 
TONSL could contribute to the phenotype in these subjects and that further genome 
sequencing studies are warranted to rule out this possibility. 
One striking finding from our study is the clinical variability of disease presentation 
and severity caused by pathogenic variants in the same gene. While the majority of 
subjects with TONSL variants were clinically diagnosed with SPONASTRIME dysplasia 
or a disorder exhibiting many features consistent with SPONASTRIME dysplasia 
(subjects 6, 7-1, 7-2, and 8), a lack of diagnostic features, such as absent metaphyseal 
striations (subject 6) or short stature (subjects 7-1 and 7-2), or the presence of atypical 
clinical abnormalities, such as severe microcephaly and primary aphakia (subject 6), and 
congenital neutropenia (subjects 7-1, 7-2, and 8), were noted in some subjects. 
Interestingly, this phenotypic variability has also been noted in other skeletal dysplasias 
caused by pathogenic variants in replication/repair genes, such as RECQL4 (MIM: 
603780) and SMARCAL1 (MIM: 606622) 43; 44. Although the underlying cause of this 
clinical heterogeneity is unclear, it is likely due, at least in part, to both the severity of the 
individual hypomorphic variants and the impact that each hypomorphic variant has on 
protein stability and/or function. Notably, several of the missense variants identified in the 
affected individuals localize within the central portion of the TONSL protein that contains 
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the ankyrin-repeats, which was previously shown to be required to mediate its interaction 
with replisome components, its accumulation at damaged forks/DNA lesions, and its 
histone chaperone and epigenetic reader activity 32; 37; 38. Furthermore, previous cell 
studies have demonstrated that deletions involving the ankyrin-repeats lead to defective 
recruitment of TONSL to sites of damaged replication forks and increased levels of 
replication-associated DNA damage 32; 37; 38. This finding suggests that the abnormal 
growth exhibited by individuals with TONSL variants may result from defective cellular 
replication beginning during development in utero. Consistent with this hypothesis, most 
subjects in our cohort with biallelic variants in TONSL presented with evidence of early 
short stature with reduced length in the newborn period. Moreover, all of the cell lines 
derived from affected individuals exhibited a significant increase in spontaneous 
replication fork stalling, which is a phenotype that is commonly observed in cell lines 
derived from individuals with replication defective-associated microcephalic dwarfism 
(MD), such as MD-DONSON (MIM: 617604), or microcephalic primordial dwarfism 
(MPD), such as ATR-Seckel Syndrome (MIM: 210600) and MPD-TRAIP (MIM: 605958)  
21; 45. However, unlike MD, individuals with variants in TONSL do not have microcephaly 
and have even lower Z-scores for height at older ages as compared to the newborn period 
suggesting that cell division in chondrocytes in the growth plate may be more severely 
impacted in this disorder. 
In addition to its role in promoting normal replication, it has been shown that 
TONSL also functions to repair and restart damaged replication forks both through its 
ability to chaperone histones 46; 47 and to facilitate RAD51 loading 40. Consequently, 
transient depletion of TONSL compromises a cell’s capacity to replicate through DNA 
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damage, particularly damage induced by the TOP1 inhibitor, CPT. All three of the subject-
derived cell lines exhibited increased levels of spontaneous replication fork stalling and 
defective formation of CPT-induced RAD51 foci, which could be rescued by the re-
expression of wild type TONSL. Interestingly, only two out of the three subject-derived 
cell lines tested exhibited a decreased ability to replicate through CPT-damaged DNA (P6 
and P7-1). In contrast, despite exhibiting increased levels of spontaneous replication fork 
stalling and defective formation of CPT-induced RAD51 foci, the cell line derived from 
subject 3-1 was able to efficiently replicate in the presence of CPT. Although unexpected, 
because TONSL has been demonstrated to be required for both processes, it is possible 
that the variants in P3-1 are ‘separation-of-function’ variants that disrupt the formation of 
RAD51 nucleofilaments at one-ended double strand breaks (DSBs) formed upon the 
CPT-induced collapse of replication forks, while still promoting replication in the presence 
of CPT via other mechanisms. Indeed, it has been suggested that RAD51, and its 
associated factors, have both HR-dependent and -independent roles in promoting DNA 
replication and repair. For example, expression of a dominant negative RAD51 mutant 
(T131P) does impact the ability of the cells to perform HR, but renders cells unable to 
efficiently repair DNA inter-strand cross-links48. Furthermore, pathogenic variants of the 
C-terminal RAD51 binding region of BRCA2 specifically compromise its role in protecting 
replication forks from uncontrolled nucleolytic processing, but still retain its ability to 
promote efficient HR-mediated repair of DSBs 49. Therefore, this indicates that an inability 
of subject-derived cells to form RAD51 foci upon DNA damage is not necessarily 
indicative of a defect in all RAD51-dependent replication and repair-associated functions, 
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and that these cellular processes should be tested specifically to ascertain the pathway 
in which the cellular defect lies.  
In addition to its role in dealing with replication-associated DNA damage, TONSL 
was recently implicated in repairing DNA DSBs 50. DSBs are predominantly repaired by 
non-homologous DNA end-joining (NHEJ) in the G1 and G2 phases of the cell cycle but 
can also be repaired by HR in late S- and G2-phase. Despite being structurally and 
biochemically distinct, the mechanisms underlying the HR-dependent repair of DSBs and 
stalled/damaged replication forks share substantial overlap. In a manner similar to 
replication-associated DNA damage, TONSL-MMS22L has been proposed to be 
recruited to newly deposited histones at sites of DSB end-resection, where it functions to 
promote HR by facilitating the loading of RAD51 50. Based on this hypothesis, it is 
tempting to speculate that the more severely affected individuals with TONSL variants 
may have defects in the repair of both replication damage and DNA DSBs, whereas those 
with a milder clinical phenotype only have deficiencies in one of the TONSL-dependent 
repair pathways.  
It is not currently clear why the TONSL variants specifically give rise to skeletal 
abnormalities. Although skeletal abnormalities, especially short stature or dwarfism, are 
actually relatively common in human syndromes caused by pathogenic variants in  
replication fork stability factors or protein involved in responding the replication blocking 
lesions, the additional skeletal features differ considerably depending on the specific gene 
that is mutated. For example, a diagnostic clinical feature of Schimke Immunoosseous 
Dysplasia (SIOD) (MIM: 242900) is spondyloepiphyseal dysplasia. In contrast, Fanconi 
Anemia (MIM: 227650) is commonly, but not invariably, associated with radial ray 
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abnormalities and vertebral anomalies. Thus, although normal replication and DNA repair 
are essential for bone development and growth, a defect in either of these processes 
does not necessarily give rise to the same specific skeletal abnormalities. Interestingly, 
however, the skeletal dysplasia phenotype associated with TONSL variants, and the 
variability of the clinical phenotype, seem to share more features in common with SIOD, 
which is caused by pathogenic variants in the DNA annealing helicase SMARCAL1 (MIM: 
606622), than other replication disorders43; 51. Although there have been no reports of 
SMARCAL1 interacting with or regulating RAD51 directly, it has been shown to promote 
the reversal of stalled/damaged replication forks, which is a prerequisite for RAD51-
dependent fork stabilization. Based on this, it is tempting to speculate that the similarities 
in skeletal abnormalities exhibited by individuals with TONSL and SMARCAL1 variants 
are linked to their ability to promote or stabilize reversed replication forks. However, why 
skeletal development would be particularly affected by loss of this function, which 
presumably would be essential for many cell types during development, is not known, 
especially since the expression of TONSL appears to be fairly ubiquitous52. Only the 
development of more clinically relevant animal models will be able to answer this 
question.  
Another interesting aspect of the clinical phenotype exhibited by individuals with 
TONSL variants is the immunologic and hematological abnormalities. While 
hypogammaglobulinemia is often observed in individuals with variants in genes involved 
in promoting DSB repair such as NBN (MIM:602667), ATM (MIM:607585), LIG4 
(MIM:601837), DCLRE1C (MIM:605988) or NHEJ1 (MIM:611290), it is not commonly 
associated with replication deficiency disorders or defects in the HR pathway 53. This 
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suggests that perhaps TONSL plays an additional role in facilitating the repair of 
specialized DSBs, particularly those associated with immune cell maturation and 
immunoglobulin gene rearrangement. In addition, several subjects exhibited neutropenia. 
Although this phenotype is relatively rare among both DNA repair and replication 
disorders, it has been documented in individuals with hypomorphic variants GINS1 
(MIM:610608) and SMARCAL154. Currently it is not clear why the neutrophil lineage is 
specifically sensitive to perturbations in DNA replication. However, the presence of 
neutropenia in individuals with TONSL variants is consistent with its role in repairing 
damaged replication forks. 
Taken together, the findings indicate that the cellular functions of TONSL are 
essential for cellular viability and that hypomorphic variants in TONSL have a deleterious 
impact at multiple stages of embryonic and postnatal development, particularly during 
skeletal development. While the underlying reason for the clinical heterogeneity arising 
from partial loss of TONSL function is unknown, further identification of additional affected 
individuals will allow us to define the full extent to which variants in this gene affect clinical 
presentation.   
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Figure 1.  TONSL variants in subjects with skeletal dysplasias.  (A)  Subject photographs and 
radiographs.   The characteristic facial features of SPONASTRIME dysplasia (midface hypoplasia 
and depressed nasal root) are more evident in subjects 2, 3-1, and 4.  Characteristic features of 
the spine are demonstrated with biconcave vertebrae in subject 4, 7-1, and 7-2 and platyspondyly 
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in subjects 2, 3-1 and 4. Metaphyseal striations are most evident in subjects 3-1 and 4. (B)  
Pathogenic variants identified in subjects with various skeletal dysplasias.  (C)  Immunoblot 
demonstrating reduced protein in subject 6 (P6) with apparently normal protein levels in subjects 
7-1 (P7-1) and 3-1 (P3-1).  DNA-PKcs was used as a loading control. The x-ray showing the 
metaphyseal striations in subject 4 is reproduced from [Sponastrime dysplasia: presentation in 
infancy, Journal of Medical Genetics, Offiah AC, Lees M, Winter RM, and Hall CM, 38, 889-93, 
2001] with permission from BMJ Publishing Group Ltd. 
 
Figure 2. (A) tonsl-/- zebrafish are larval lethal and show progressively diminished size 
compared to wild-type siblings. Food intake is variable in mutants and correlated with 
reduced fitness and mortality (gut contents indicated with white arrows). (B) tonsl-/- fish 
(red) are not significantly smaller than wild-type siblings (blue) at 6 dpf (days post 
fertilization) or 8 dpf, but are on average smaller at later timepoints through 13 dpf (N ³ 
10 larvae for each timepoint; p = 0.045 at 10 dpf; p < .0001 at 13 dpf). Normal zebrafish 
growth during this stage varies widely, and survivor bias is a factor in these data as tonsl-
/- mutants begin to die at 8 dpf. (C) tonsl mutants exhibit precocious ossification of the 
axial skeleton. Bone formation is visualized by staining with Alizarin red, and cartilage is 
stained with Alcian blue. At 7 dfp, vertebral development is marked by bony centra forming 
around the notochord (asterisks).  Significantly more centra have formed by this stage in 
homozygous tonsl mutants compared to wild type siblings. WT: 4.100 ± 0.5667, n=10; tonsl-
/-: 8.867 ± 0.4350, n=15 larvae. (D)  Wild type larvae have a high concentration of neutrophils 
in the gut (dashed outline) and neutrophils are dispersed throughout the circulatory 
system (Do). mpo:gfp;tonsl-/- mutants have variable neutrophil distribution correlated with 
their decline in health, ranging from normal (D’) to reduced neutrophil fluorescence in the 
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gut (D’’, D’’’), to diminished numbers of circulating neutrophils observable in blood vessels 
of the head and trunk (D’’’). (E) The number of circulating neutrophils in mpo:gfp;tonsl-/- 
is reduced in mutants showing signs of decline (D’’’, red) compared to stage-matched wild 
type (blue). Gut neutrophils were excluded from this count (N = 10; p < .0001). Scale bars 
in A, D: 1mm; in C: 500nm. Student’s t-tests with Welch’s Correlation were performed for 
each data set. Data in (B) is mean +/- SD. 
 
Figure 3.  Impact of TONSL variants on CPT-induced RAD51 foci formation.  (A) Cell 
lines derived from individuals with biallelic TONSL variants exhibit defective recruitment 
of RAD51 foci to CPT induced DNA damage.  RAD51 foci formation was analyzed by 
immunofluorescence in subject-derived fibroblasts exposed to 1 µM CPT, and the 
percentage of cells with pan-nuclear γH2AX staining with ‘strong’ RAD51 foci was 
quantified. ATLD2 is a fibroblast cell line derived from an individual with a confirmed 
genetic diagnosis of ataxia telangiectasia-like disorder (pathogenic variants in MRE11) 
and was used as a control. N = 3 independent experiments. A minimum of 400 cells were 
counted per experiment. For statistical analysis, Student’s T-Test was performed (** = p 
< 0.01, *** = p < 0.001). Data in (A) show mean values and error bars denote SEM, and 
representative images are shown in (B). 
 
Figure 4. Cell lines from individuals with biallelic TONSL variants exhibit increased levels 
of spontaneous replication fork stalling, and defective replication fork progression in the 
presence of CPT. (A) Schematic for DNA fiber analysis in the absence or presence of 
exogenous replication stress. Subject-derived cell lines were pulsed with CldU for 30 
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minutes, and then pulsed with IdU, or IdU with 50 nM CPT, for 30 minutes. (B) DNA fiber 
analysis on subject-derived fibroblast cell lines. The percentage of ongoing forks (left) or 
stalled forks (right) in the absence of exogenous DNA damage were quantified. 
Representative images of ongoing forks and stalled forks are included below. A minimum 
of 850 fork structures in total were counted over 3 independent experiments. For 
statistical analysis, Student’s T-Test was performed. Error bars denote SEM.  (C) Dot 
density graph representation of the ratio of IdU tract length / CldU tract length in untreated 
and CPT treated patient-derived fibroblasts. N = 3 independent experiments. A minimum 
of 100 ongoing fork structures were counted per experiment. Red lines denote mean 
values. For statistical analysis, Mann-Whitney rank sum test was performed. In all cases 
* = p < 0.01, ** = p < 0.01 and *** = p < 0.001.  
 
Figure 5. Wild Type TONSL rescues CPT-induced RAD51 foci formation and corrects the 
replication abnormalities observed in subject-derived fibroblasts.  (A) Representative 
immunoblot analysis of TONSL in fibroblasts derived from subjects P3-1 and P6 infected 
with lentiviruses encoding wild type Flag-tagged TONSL or an empty vector. DNA-PKcs 
was used as a loading control. (B and C) Fibroblasts cell lines from (A) were exposed to 
1µM CPT, and the percentage of cells with RAD51 foci formation was quantified as in 
Figure 3A. A minimum of 1000 cells in total were counted over 3 independent 
experiments. For statistical analysis, Student’s T-Test was performed. Error bars denote 
SEM. Representative images are shown in (B). (D) DNA fiber analysis was performed on 
subject-derived fibroblasts cell lines expressing either Flag-tagged wild type TONSL or 
an empty lentiviral vector. The percentage of stalled forks in untreated cells was 
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quantified. A minimum of 350 fork structures in total were counted over 3 independent 
experiments. For statistical analysis, Student’s T-Test was performed. Error bars denote 
SEM. (E) Dot density graph representation of the ratio of IdU tract length / CldU tract 
length in CPT treated fibroblasts. A minimum of 200 fork structures in total were counted 
over 3 independent experiments. For statistical analysis, Mann-Whitney rank sum test 
was performed.  Red lines denote mean values. In all cases: *** = p < 0.001; ** = p < 
0.01. 
 
Figure 6. Subject-derived fibroblasts exhibit increased levels of spontaneous 
chromosomal aberrations. (A) Metaphase spreads were prepared from subject-derived 
fibroblast cell lines expressing either Flag-tagged wild type TONSL or an empty lentiviral 
vector. The average number of spontaneous chromosomal aberrations per metaphase 
was quantified. N = 3 independent experiments. A minimum of 32 metaphases were 
counted for each experiment. For statistical analysis, Student’s T-Test was performed 
(*** = p < 0.001). Error bars denote SEM. Representative images of metaphase spreads 
























Table 1.  Skeletal Features of Subjects Diagnosed with SPONASTRIME Dysplasia 
Subject ID 1 2 3-1 3-2 4 5 13 14 15 
Sex F F M M F F M  F M 
Age at last follow-up 7 y 9 m 7 y 11 m 4 y  9 m 9 m 22 y  23 y 17 y 10 m 4 y 11 y 
Height  (Z-score) -3.3 -4.2 -5.0 -9.0 -10.8 -8.8 -5.1 -6.7 -6.0 
Weight  (Z-score) -0.1 -1.2 -2.1 -5.1 -4.2 -3.0 -2.4 -2.2 -4.0  
FOC (Z-score) Not available Not available -0.6 Not available -3.4 -2.1 0.6 -1.0 -3.0 
Disproportionate 
Short Stature 
Yes Yes Yes Yes Yes Yes No Yes Yes 
Orthopedic 
Abnormalities 
































         
Metaphyses Widened 
metaphyses 




































Normal Unknown Normal Normal Normal Small, 
delayed 
ossification 










































necks; Coxa vara; 
Ivory epiphyses 
(hand);  Dislocated 








None Slightly short 
and wide 
femoral necks 




Table 2.  Variants in TONSL in Subjects with Clinical Diagnosis of SPONASTRIME Dysplasia 
Family ID 1 2 3 4 5 13 14 15 



















1 / 150710 21 / 239692 1 / 150710 1 / 30966 21 / 239692 Not present 1 / 150710 1 / 150710 












Sift Damaging Damaging Damaging Tolerated Damaging N/A Damaging Damaging 
CADD 16.77 21.3 16.77 16.12 21.3 N/A 16.77 16.77 

















2 / 243938 Not present Not present Not present Not present Not present 2 / 251402 2 / 219724 
Polyphen N/A N/A Probably damaging N/A N/A N/A N/A N/A 
Sift N/A N/A Damaging N/A N/A N/A N/A N/A 
CADD N/A N/A 15.56 N/A N/A N/A N/A N/A 
All coordinates utilize hg19, NM_013432.4. Parental DNA for subjects 13 and 15 were not available to ascertain segregation. Variant c.122-5C>G was assessed 
















Table 3.  Skeletal Features for Subjects Without a Clinical Diagnosis of SPONASTRIME Dysplasia 
 
Subject ID 6 7-1 7-2 8 









Sex F F M F 
Age at last follow-
up 
12 y 10 y 9 m 9 y 9 m 5 y 11 m 
Height  
(Z-score) 
-10.6 -1.5 -1.6 -6.5 
Weight  
(Z-score) 
-5.1 -0.2 0.8 -5.3 
FOC 
 (Z-score) 
-8.0 0.1 -1.0 -4.3 
Disproportionate 
short stature 
No No No Yes 
Orthopedic 
Abnormalities 
Long tapering fingers 
and proximally inserted 
thumbs; Long and 
overlapping toes 
Pes planus None Rhizomelia and 
mesomelia;  
5th finger clinodactyly 
Radiographic 
Features 
    
Metaphyses Irregular Mild metaphyseal 
irregularities with mild 
striations 
Mild widening and 
irregularities with mild 
striations  
Broad, flared, and  
irregular metaphyses with 
mild striations 
Epiphyses Normal Normal Normal Normal 
Spine Platyspondyly Biconcave vertebrae Biconcave vertebrae Platyspondyly 
Other Skeletal 
Findings 
None Short, wide, femoral 
necks 
Short, wide, femoral 
necks 
















Table 4.  Variants in TONSL in Subjects without a Clinical Diagnosis of SPONASTRIME Dysplasia 
 
 
Family ID 6 7 8 
Variant 1 c.2137C>T, p.(Gln713*) c.866-1G>C 
c.329G>A, 
p.(Trp110*) 




Not present Not present Not present 
Polyphen N/A N/A N/A 
Sift N/A N/A N/A 
CADD N/A 11.62 N/A 









4 / 244636 Not present Not present 
Polyphen Probably damaging Probably damaging Probably damaging 
Sift Damaging Damaging Damaging 
CADD 20.8 36 21.5 
 




Table 5.  Early embryonic lethality in Tonsl-/- mouse  
 
 Postnatal Day 14 Embryonic Day 9.5 
Tonsl+/+ 59 7 
Tonsl+/- 125 26 
Tonsl-/- 0 0 
   
Chi square, df 52.63, 2 10.43, 2 
p value <0.0001 0.0054 
 
 
 Table S1.  Primers used for Sanger sequencing of human TONSL 
Exons 5’ primer 3’ primer Amplicon 
size (nt) 
hTONSLex1-2 GGCCGACCGTACTTCCC CTCCTGCCAGTGCTGCTC 636 
hTONSLex3 CAAGGCGAAAGCCAAGG AACCTACTCCTGCCCCAGTC 586 
hTONSLex4 AGCAAGAACAGGGTCTCTGG GCTCCAGAAGACGGGATTG 373 
hTONSLex5 GGCCCAAAGCTGGAAAC ACTTCCTCCAGGAACAAGGG 249 
hTONSLex6-7 CCGTGTGGCATCAGCAG GGCTCACCCCTGCACAC 492 
hTONSLex8-9 TCACAGCTTGCAGGTGGTAG GTCCTGAGGCAGAGACATGG 524 
hTONSLex10-11 CCGTTGGACGCAGACAG CACAGCACACCCCTCTCC 578 
hTONSLex12-13 CTGCTAACCTTCACCTCCC CACAAACGCACAGCTCCTC 380 
hTONSLex14-15 TAGGCTGCAGAGCTCACG AGTTGAGCAGGGGCACAG 483 
hTONSLex16 ACTCGAAAGGTGAGCCTGG CGGGGACTCTCAGCGTAG 263 
hTONSLex17_1 GATGCTCCATCACAGGTGG AAGGGCTTTGCTGTGGC 508 
hTONSLex17_2 ACAGGGAAGCAGCCACAG AGTGGGCTCCACCCTACAC 509 
hTONSLex18 AGGCAGGTGTAGGGTGGAG ACCCTGACATGCAAACACG 217 
hTONSLex19-20 GCATTACCCCGGCTGTG TGGTGGAGCCTGTGTGC 481 
hTONSLex21 GATTCAGAGGGCAGAAAGGG GGACCTGCAGAATGGGAAC 423 
hTONSLex22 GACTGCCAAGCCAAGCC GTCCTGGAAACCCTCAATGC 312 
hTONSLex23 AGAACTTGGGGTGGGTACAG GAGCTCCTCCCAGCAACC 313 
hTONSLex24 TGCTGGGAAGCAGGCAG CCTTCTCCCATAGGGTCCAG 212 
hTONSLex25 GCAGCTTTCCTAGTGTTGGG CACCTGGGTCTCAGGCAG 274 
hTONSLex26 TCCTGGCATCTGTACCTTCC AAGCCCGGTCTTACCCC 1008 
 Table S2.  Additional Subject Characteristics for Subjects with Clinical Diagnosis of SPONASTRIME Dysplasia 
Subject ID 1 2 3-1 3-2 4 5 13 14 15 
Sex F F M M F F M  F M 
Age at last 
follow-up 
7 y 9 m 7 y 11 m 4 y  9 m 9 m 22 y  23 y 17 y 10 m 4 y 11 y  
Birth 
Parameters 
         
Gestational 
Age 
Not available Full term 40 weeks 40 weeks 40 weeks 38 weeks Full term 39 weeks 39 weeks 
Length Not available -3.71 -1.16 -3.41 -2.83 -1.89 Not available -0.23 -2.94 
Weight Not available -2.70 -4.71 -1.78 -2.18 -1.01 Not available -2.03 -2.11 
FOC Not available Not available Not available -0.38 -2.32 -0.41 Not available -2.26 Not available 
Extra-Skeletal 
Features 
         
Dental Unknown Short dental 
roots; 
Malocclusion 
with early loss 
of teetha 
Normal None Shallow dental 
roots 
Malocclusion








Short dental roots; 
Dental crowding 
































upturned nose and 





Eye Unknown Bilateral 
cataracts (age 
~10 years)a 
None None Bilateral 
cataracts 
(extracted at age 






Normal  None Normal 



















































Normal None Normal 
 Development Normal Normal Expressive 
language 
delay 

































None At age 30 y, weight 
40.8 kg (-4.3SD) an 
height 130.8 cm (-
6.2SD). Family 
history includes two 
maternal third 
cousins (12 y/o 
female, 10 y/o 




















 Table S3.  Subjects with clinical diagnosis of SPONASTRIME dysplasia but without Biallelic Variants in TONSL 
Subject ID 91 102 113 12 
     
Sex M M F M 
Age at last follow-up 5 y 9 m 15  y 7 m 14 y 15 y 1 m 
Height  
(Z-score) 
-5.6 -5.36 -6.4  -1.61 
Weight  
(Z-score) 
-0.19 -4.09  -3.8  -0.61 
FOC 
 (Z-score) 
Not available 0.10 -2.6  0.42 
Disproportionate Short Stature Unknown Yes Yes No 
Birth Parameters     
Gestational Age Unavailable Full Term 39 weeks Not Available 
Length Unavailable 48.26 cm NA Not Available 
Weight Unavailable 2807 g -1.3 Not Available 
FOC Unavailable Not Available Not Available Not Available 
Clinical Features     
Dental Short dental roots Mandibular overbite and wide 
spaced teeth 
Extensive dental caries Misaligned 
Facial Features Midface hypoplasia; Bifrontal 
bossing, Prominent mandible 
Prominent forehead; Midface 
hypoplasia; 
Mild prognanthism;  
 Mildly coarsened facial 
appearance  
 
Frontal bossing;  
Midface hypoplasia 
Mild malar hypoplasia; Low-set 
ears 
Eye Bilateral subcapsular cataracts at 
age 11 years 
Normal dilated examination;  
Bilateral epicanthal folds 
Strabismus Epicanthi 
Nose Depressed nasal bridge Depressed nasal bridge; 
Anteverted nares 
Saddle nose Depressed and large nasal 
bridge 
 
Immunologic Hypogammaglobulinemia; Poor 
antibody response to tetanus and 
Haemophilus vaccinations 
None known Clinically normal Clinically normal 
Orthopedic Mild genu valgum; Limitation in 
extension of elbows; Mild joint 
laxity 
Bilateral genu valgum; 
Brachydactyly; Progressive 
kyphoscoliosis requiring T2-L4 
posterior spinal fusion at age 11 
years 
No other issues Scoliosis surgery 
Development Normal Normal Severe intellectual disability Normal 
Radiographic Features     
Metaphyses Irregularities with striations Mild metaphyseal irregularities; 
Metaphyseal striations evident at 
age 10 years. 
Striations Striations with sclerosis 
Epiphyses Epiphyseal abnormalities Normal Normal Normal 
Spine Platyspondyly Platyspondyly; Ovoid and 
biconcave vertebral shape, 
Thoracic kyphosis; Increased 
lumbar lordosis indentation of 
Biconvex vertebrae with reduced 
posterior vertical height, left 
 Reduced height of vertebral 
bodies; Anterior portion of the 
vertebral body is taller than 
posterior portion with central 
anterior protuberance 
hypoplastic dens without 
instability  
vertebral endplates, thickened 
endplates, reduced height 
thoracic scoliosis, surgically 
fused T4-L1 at age 12. 
Other Skeletal Findings Coxa vara Short and wide femoral necks; J-
shaped sella; Proximal pointing 
of the 3rd, 4th and 5th metacarpals; 
Mild osteopenia 
 
Carpal ossification delay; 
Brachymetacarpia 
Sclerotic zones in phalanges, 
metacarpal and metatarsal bone 
Other  Mildly limited bilateral elbow 
extension; 
Hypernasal voice; Multiple otitis 




1  Heterozygous variant in TONSL noted (NM_013432.4:c.2800C>T, p.(Arg934Trp), rs75557541) but no second variant detected.  
Patient was previously published1,2. 
2 Heterozygous variant in TONSL noted (NM_013432.4:c.25+2dupT) but no second variant detected.   







 Table S4. Additional Subject Characteristics for Subjects without Clinical Diagnosis of 
SPONASTRIME Dysplasia 
Subject ID 6 7-1 7-2 8 









Sex F F M F 
Age at last 
follow-up 
12 y 10 y 9 m 9 y 9 m 5 y 11 m 
Birth 
Parameters 
    
Gestational 
Age 
34 weeks 39 5/7 weeks 37 4/7 weeks 35 2/7 weeks 
Length -2.64 0.36 1.33 -2.54 
Weight -1.54 -0.34 -0.49 -1.91 




    
Dental Delayed tooth 
eruption, small teeth 
Delayed tooth eruption; 
Tooth discoloration;  
High palate 
Delayed tooth eruption; 
Tooth discoloration; 






High forehead, frontal 
bossing; Hypoplasia 
of supra-orbital ridges 
Short philtrum Poorly defined philtrum Short philtrum 








secondary to aphakia 
Wears glasses No known abnormalities Epicanthal folds with 
mild synophrys 
Nose Broad and depressed 
nasal bridge with 
crease over the 
bridge;  
Anteverted nares 
Bulbous tip Broad and depressed and 
nasal bridge 


















of infancy; Low memory 
B cell percentages 
Congenital neutropenia 
with normocellular bone 
marrow with myeloid 
hypoplasia and left shift; 
Failure to respond to the 
polysaccharide-restricted 
serotypes in the 23-
valent  pneumococcal 
vaccine; Recurrent 
infections 




Normal Normal Mild global delay, now 
resolved 
 Other Osteopenia; Low set 
ears; High-arched 
palate 
Brittle toe nails Growth hormone 
deficiency via glucagon 
stimulation test; Absence 
seizures; Dystrophic 
toenails 
Asymmetric renal length; 
Multiple otitis media 




1. Gripp, K.W. et al. Expanding the phenotype of SPONASTRIME dysplasia to include short 
dental roots, hypogammaglobulinemia, and cataracts. Am J Med Genet A 146A, 468-73 
(2008). 
2. Langer, L.O., Jr., Beals, R.K., LaFranchi, S., Scott, C.I., Jr. & Sockalosky, J.J. 
Sponastrime dysplasia: five new cases and review of nine previously published cases. Am 
J Med Genet 63, 20-7 (1996). 
3. Camera, G., Camera, A., Di Rocco, M. & Gatti, R. Sponastrime dysplasia: report on two 















 Table S5.  Exome Coverage Statistics and Number of Rare or Novel Variants Identified and 
Analyzed in the Exomes 
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Rare or novel 
variants (SNVs and 
indels) 
782 997 433  342 641 697 677 438 716 271 861 525 484 274  
Rare or novel 
variants in known 
skeletal dysplasia 
genes 
9 14 3  NA NA 4 4 9 11 NA 8 9 8 NA  
Rare or novel 
variants in genes 
explaining the 
phenotype 









Figure S1.  Additional photographs.  (A)  Subject 2 at 6 years of age showing rhizomelia, 
mesomelia and genu valgum. (B)  Subject 4 at 22 years of age.  Additional radiographs and 
photographs have been published previously (8). (C) Subject 6 at 12 years of age.  (D) Twisted 
lateral incisors observed in subject 4 (bilateral).  (E)  Twisted lateral incisor observed in subject 7-2 
(unilateral).
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Figure S2. Additional radiographs. (A) Subject 1, 6 years 8 months. Metaphyseal widening and irregularities are apparent in tibia.
(B) Subject 1, childhood, age unknown. Metaphyseal striations and irregularities are apparent in tibia and femur. (C) Subject 1, 13
years, 3 month. Femoral necks appear short and wide. (D) Subject 5, 11 years. Metaphyseal striations and irregularities are noted in
tibia and femur with varus bowing. (E) Subject 5, 11 years. Platyspondyly and biconcave vertebrae are noted. (F) Subject 8, 1 year
5 months. Platyspondyly noted. Several of the vertebral bodies also have a biconcave shape. Note the distinct junction between
anterior and posterior portions of the lumbar vertebral bodies. (G) Subject 8, 4 years 5 months. Widening, sclerosis, and irregularity
and mild striations of the distal femoral metaphysis are noted. (H) Subject 8, 4 years 5 months. Widening, sclerosis, and irregularity
and mild striations of the proximal tibial metaphysis are noted.
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Figure S3. Tonsl deletion analysis. (A) Schematic
representation of the Tonsl locus. The exon/intron
structure of the wild-type and null (Tonslem1(IMPC)Bay)
allele are shown. Exons 12-18 are deleted in the null
allele. Blue boxes = coding sequence; White boxes =
UTRs. Scissors represent sgRNA target sites. Arrows
indicate primers P1, P2, and P3 used for genotyping and
sequencing (P1 and P2 amplify the wild-type allele; P1
and P3 amplify the null allele). (B) Distal
(Chr15:76,635,014-76,635,013; GRCm38/mm10) and
proximal (Chr15:76,632,474-76,632,473;
GRCm38/mm10) breakpoints of the deletion in
Tonslem1(IMPC)Bay. Tonsl is oriented in the antisense
direction in the mouse genome. Sequence text in black
and gray are the sgRNA target and protospacer adjacent
motif (PAM) sequences. Red sequence text is an 8 bp
insertion that occurred during nonhomologous end
joining (NHEJ). (C) Chromatogram showing DNA






tonslb1348 c.235-47; p. E80S4Ter
Figure S4.  Zebrafish CRISPR mutants.  Frameshift alleles of tonsl affect the two alternate reading frames of exon 3. Bases deleted 
in each allele are boxed in red; homozygous mutant sequence is presented on the left for each allele.
